The company had reported a net profit of Rs 195.06 crore in the April-June quarter of financial year 2013-14.
Cadila's net sales in the quarter under review were up by 25.68% to Rs 2,020.38 crore as against Rs 1,607.45 crore in the year-ago period, the company said in a BSE filing.
Also Read
"Sales growth was buoyed by the company's formulations business in the US, which grew by 88% during the quarter," the company said in a statement.
Overall expenses in Q1 stood at Rs 1,741.71 crore, up 24.55%, compared with Rs 1,398.38 crore in the same quarter of last fiscal.
Cadila Healthcare shares were trading at Rs 1,169 apiece in afternoon trade, up 3.53% from previous close on the BSE.